Evidence map›Paper›PMID 34633844›Full record

ArticleAntimicrobial agents and chemotherapy2022

Population Genomics Reveals Distinct Temporal Association with the Emergence of ST1 Serotype V Group B Streptococcus and Macrolide Resistance in North America.

M Belén Cubria, Luis Alberto Vega, William C Shropshire, Misu A Sanson, Brittany J Shah, Shrijana Regmi, Marcia Rench, Carol J Baker, Anthony R Flores

Open access · greenAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Towards a holistic epidemiology ofFrontiers in bioinformatics · 2026
    Article
  3. Article
  4. Article
  5. Genomic Analysis of Group BOpen forum infectious diseases · 2023
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

M Belén CubriaDivision of Infectious Diseases, Department of Pediatrics, McGovern Medical School, University of Texas Health Sciences Center at Houston, Houston, Texas, USA.
Luis Alberto VegaDivision of Infectious Diseases, Department of Pediatrics, McGovern Medical School, University of Texas Health Sciences Center at Houston, Houston, Texas, USA.
William C ShropshireDepartment of Infectious Diseases, Infection Control, and Employee Health, MD Anderson Cancer Center, Houston, Texas, USA.
Misu A SansonDivision of Infectious Diseases, Department of Pediatrics, McGovern Medical School, University of Texas Health Sciences Center at Houston, Houston, Texas, USA.
Brittany J ShahDivision of Infectious Diseases, Department of Pediatrics, McGovern Medical School, University of Texas Health Sciences Center at Houston, Houston, Texas, USA.
Shrijana RegmiDivision of Infectious Diseases, Department of Pediatrics, McGovern Medical School, University of Texas Health Sciences Center at Houston, Houston, Texas, USA.
Marcia RenchSection of Infectious Diseases, Department of Pediatrics, Texas Children's Hospital and Baylor College of Medicinegrid.39382.33, Houston, Texas, USA.
Carol J BakerDivision of Infectious Diseases, Department of Pediatrics, McGovern Medical School, University of Texas Health Sciences Center at Houston, Houston, Texas, USA.
Anthony R FloresDivision of Infectious Diseases, Department of Pediatrics, McGovern Medical School, University of Texas Health Sciences Center at Houston, Houston, Texas, USA.ORCID 0000-0002-6402-4269
The University of Texas Health Science Center at Houston · USBaylor College of Medicine · USThe University of Texas MD Anderson Cancer Center · US

Funding

Texas Medical Center Training Program in Antimicrobial ResistanceT32AI141349 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI GARSIN, DANIELLE A · 2019 to 2023
$1.3M
Evolution and pathogenesis of serotype V group B Streptococcus in humansR21AI153663 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI FLORES, ANTHONY RICHARD · 2021 to 2022
$429k
NIAID NIH HHS R21 AI153663NIAID NIH HHS T32 AI141349
6 · The paper itself

Abstract

Identified in the 1970s as the leading cause of invasive bacterial disease in neonates and young infants, group B Streptococcus (GBS) is now also recognized as a significant cause of morbidity and mortality among adults with underlying medical conditions and the elderly. Concomitant with the increasing incidence of GBS invasive disease in adults is the rise of resistance among GBS isolates to second line antibiotics. Previous research shows that among serotype V GBS, one of the most common capsular types causing adult invasive disease, sequence type 1 (ST1), accounts for an overwhelming majority of adult invasive disease isolates and frequently harbors macrolide resistance. In this study, using whole-genome sequencing data from strains isolated in the United States and Canada over a 45-year period, we examined the association of antimicrobial resistance with the emergence of invasive serotype V ST1 GBS. Our findings show a strong temporal association between increased macrolide resistance and the emergence of serotype V ST1 GBS subpopulations that currently co-circulate to cause invasive disease in adults and young infants. ST1 GBS subpopulations are defined, in part, by the presence of macrolide resistance genes in mobile genetic elements. Increased frequency of macrolide resistance-encoding mobile genetic elements among invasive GBS ST1 strains suggests the presence of such elements contributes to GBS virulence. Our work provides a foundation for the investigation of genetic features contributing to the increasing prevalence and pathogenesis of serotype V GBS in adult invasive disease.

Indexed as

Anti-Bacterial AgentsStreptococcal InfectionsAdultAgedDrug Resistance, BacterialHumansInfantInfant, NewbornMacrolidesMetagenomicsSerogroupSerotypingStreptococcus agalactiaeAnti-Bacterial AgentsMacrolidesgenomicsgroup B streptococcusmacrolide resistanceserotype V

Identifiers

PMID34633844
PMCPMC8765267
OpenAlexW3206754265

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.